Advertisement

Clinical Management

  • Marcus L. QuekEmail author
  • Trinity J. Bivalacqua
  • Ashish M. Kamat
  • Mark P. Schoenberg
Chapter

Abstract

Urine cytology is utilized in various clinical scenarios, including the evaluation of hematuria or voiding symptoms, the initial workup for a suspected urothelial malignancy, and for ongoing surveillance following treatment for urothelial cancer. The primary goal of the clinician evaluating these patients is to ensure that a potentially lethal urothelial malignancy is not missed. When combined with upper tract radiographic imaging and direct cystoscopic evaluation, urine cytology provides a powerful means to accomplish this goal.

Keywords

Transurethral resection of bladder tumor Cystoscopy Radical cystectomy Intravesical chemotherapy Intravesical immunotherapy Bacillus Calmette-Guerin (BCG) Mitomycin C CT urography Urethral recurrence Upper tract urothelial carcinoma 

References

  1. 1.
    Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33:66. e25–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Mitra AP, Alemozaffar M, Harris BN, Schuckman AK, Skinner EC, Daneshmand S. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology. 2014;84:1420–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004;172:1342–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol. 2007;177:2088–94.CrossRefPubMedGoogle Scholar
  10. 10.
    Stein JP, Penson DF, Wu SD, Skinner DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol. 2007;178:756–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63:4–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Bubendorf L, Piaton E. UroVysion(R) multiprobe FISH in the triage of equivocal urinary cytology cases. Ann Pathol. 2012;32(6):e52–6. 438–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Yoder BJ, Skacel M, Hedgepeth R, Babineau DF, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301.CrossRefPubMedGoogle Scholar
  14. 14.
    Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, et al. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67:876–88.CrossRefPubMedGoogle Scholar
  16. 16.
    Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11:589–96.PubMedGoogle Scholar
  17. 17.
    Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190:1181–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Herr HW. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. Eur Urol. 2015;67:605–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015;121:169–78.CrossRefPubMedGoogle Scholar
  20. 20.
    Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184:1907–13.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66:863–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192:305–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015;29:237–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol. 2005;174:93–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson Cancer experience. J Urol. 2004;172:481–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Marcus L. Quek
    • 1
    Email author
  • Trinity J. Bivalacqua
    • 2
  • Ashish M. Kamat
    • 3
  • Mark P. Schoenberg
    • 4
  1. 1.Department of UrologyLoyola University Health Systems, Loyola UniversityChicagoUSA
  2. 2.Department of UrologyThe Johns Hopkins Hospital, The Johns Hopkins UniversityBaltimoreUSA
  3. 3.Department of UrologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of UrologyMontefiore Medical Center, Albert Einstein College of Medicine of Yeshiva UniversityBronxUSA

Personalised recommendations